James Matcham
52 works · 6,072 citations · h-index 22
Top works
- Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension
- Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension
- Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia
- Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension
- Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension
- Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study
- Impact of a five-dimensional framework on R&D productivity at AstraZeneca
- The effect of climatic factors on Colletotrichum gloeosporioides, causal agent of mango anthracnose, in the Philippines
- Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
- Differences between graft product and donor side effects following bone marrow or stem cell donation
- A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia
- Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry‐sponsored clinical trials
- Imprecision of counting CFU-GM colonies and CD34-expressing cells
- Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
- Decision‐making in early clinical drug development
- Missing data: Discussion points from the PSI missing data expert group
- Making available information from studies sponsored by the pharmaceutical industry: some current practices
- Granulocyte Colony-Stimulating Factor: Biology and Clinical Potential
- Embracing model-based designs for dose-finding trials